赛诺菲：首个用于延缓1型糖尿病进展的创新药特瑞可在华获批

Core Insights - Sanofi announced that its drug, Trelagliptin (trade name: Trelioza), has been approved by the National Medical Products Administration (NMPA) in China for use in children aged 8 and above and adults with type 1 diabetes stage 2, aimed at delaying progression to stage 3 diabetes [2] Company Summary - Sanofi's Trelagliptin is now approved for a new indication in China, which may enhance its market presence and sales potential in the diabetes treatment segment [2] Industry Summary - The approval of Trelagliptin reflects ongoing advancements in diabetes management and treatment options available for patients, particularly in the pediatric and adult populations [2]